摘要
目的 探讨糖皮质激素在IgA肾病治疗中的价值,为其临床干预治疗提供依据。方法 对应用糖皮质激素治疗的79例IgA肾病患者的临床资料进行回顾性分析。结果 79例IgA肾病患者肾组织活检后平均随访( 39. 6 ±42. 2 )个月;治疗前尿蛋白量为( 1. 57 ±2. 40 )g/24 h, 治疗后则降到(0. 43±1. 07)g/24h(P=0. 000 );治疗前平均内生肌酐清除率为( 86. 64±29. 99 )ml/min,治疗后为(92. 06±35. 90)ml/min(P>0. 05)。同时不同蛋白尿程度、有无高血压、治疗前有无肾功能受损及不同的肾脏病理表现的患者激素治疗后尿蛋白水平均显著降低。结论 应用糖皮质激素治疗IgA肾病能显著降低其患者的蛋白尿,保护肾功能。
Objective To explore the value of glucocorticoid in the treatment of IgA nephropathy and to provide basis for clinical intervention treatment.Methods Clinical data of 79 cases of IgA nephropathy treated with glucocorticoid were retrospectively analyzed.Results 79 patients were followed up for (39.6±42.2) months after biopsy of renal tissue.Urine protein decreased from (1.57±2.40) g/24 h to (0.43±1.07)g/24 h(P=0.000) after treatment with glucocorticoid.Endogenous creatinine clearance rate increased from (86.64±29.99) ml/min to (92.06±35.90) ml/min (P>0.05) after treatment with glucocorticoid.The urine protein level in the patients with different urine protein,hypertension,renal injury and pathological feature significantly decreased.Conclusion Glucocorticoid can significantly decrease urine protein and protect renal function.
出处
《中国综合临床》
北大核心
2005年第6期511-513,共3页
Clinical Medicine of China
